Phase II Randomized Trial of Biweekly Bevacizumab, Capecitabine, Oxaliplatin and Irinotecan (BEV- CAPEOXIRI) Versus Triweekly Bevacizumab, Capecitabine and Oxaliplatin (BEV- CAPEO

NEO-ADJUVANT VERSUS ADJUVANT USE OF BEVACIZUMAB IN THE MANAGEMENT OF ADVANCED OVARIAN CANCER

Paclitaxel/carboplatin versus carboplatinin patients with epithelial ovarian cancer

Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment

Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine as First-Line Therapy for Metastatic Triple Negative Breast Cancer

Interval debulking Surgery after Neoadjuvant Chemotherapy for Advanced Ovarian Carcinoma, Impact on Patients’ Survival

ADVANCED EPITHELIAL OVARIAN CANCER: THE PROGNOSTIC SIGNIFICANCE OF RESIDUAL DISEASE AFTER CYTOREDUCTIVE SURGERY

CONCURRENT CHEMO-RADIOTHERAPY OF WEEKLY PACLITAXEL VERSUS WEEKLY CARBOPLATIN IN LOCALLY ADVANCED HEAD AND NECK CARCINOMAS UNFIT FOR CISPLATIN

Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients

Weekly cisplatin (40 mg/m2) versus three-weekly (100mg/m2) cisplatin delivered concurrently with radiotherapy in high risk head and neck cancer patients